An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Pulse Biosciences (Nasdaq: PLSE) will report its third quarter 2022 financial results on November 10, 2022, after market close. A conference call will follow at 1:30pm PT / 4:30pm ET, where management will discuss the results. Investors can join the call by dialing 1-877-704-4453 (domestic) or 1-201-389-0920 (international), and a webcast will be available at investors.pulsebiosciences.com.
Positive
The CellFX® System leverages patented Nano-Pulse Stimulation technology for various medical applications.
The company is pursuing multiple applications in sectors like cardiology and oncology which could expand market reach.
Negative
No financial metrics or updates regarding revenue or earnings guidance were provided in the PR.
HAYWARD, Calif.--(BUSINESS WIRE)--
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third quarter of 2022 after market close on Thursday, November 10, 2022. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET.
Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nano-Pulse Stimulation (NPS) technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The CellFX® System is the first commercial product to harness the distinctive advantages of NPS technology to treat a variety of conditions for which an optimal solution remains unfulfilled. The Company is actively pursuing application development for the use of NPS technology in cardiology, oncology, gastroenterology, and other medical specialties. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. Visit pulsebiosciences.com to learn more.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.
